The 2026 NHP GMP Reset: How GUI-0158 and the End of FSRNs Reshape Site Licence Compliance

Canada's natural health product (NHP) sector has entered a demanding compliance transition. Two changes from Health Canada now sit at the centre of every importer and distributor file. The first is the updated Good Manufacturing Practices Guide for Natural Health Products, known as GUI-0158, which came into force on March 4, 2026. The second is the end of the Foreign Site Reference Number, or FSRN, process, which Health Canada eliminated on February 16, 2026.

Taken together, these two moves reset how foreign manufacturing and warehousing sites prove their good manufacturing practices (GMP) status to Health Canada. Companies that once relied on a shared FSRN to move product into Canada now face a very different reality. The evidence must travel with each importer's natural health product site licence application, and the documentation bar is higher than many supply chains are ready for.

This article explains what changed, why it matters, and the practical steps NHP manufacturers, importers, distributors, and brand owners should take right now to close the gap before it becomes an inspection finding.

Executive Summary

Health Canada has tightened the site licensing pathway for NHPs on two fronts at once. GUI-0158, version 4.0, is the current interpretation of the GMP requirements in Part 3 of the Natural Health Products Regulations (SOR/2003-196), and it has been in force since March 4, 2026. Separately, and effective immediately on February 16, 2026, the FSRN process was discontinued.

The result is a real and widespread compliance gap. Importers can no longer point to a pre-cleared FSRN to satisfy foreign site GMP evidence. Instead, each importer must submit complete GMP evidence, a recognized GMP certificate or a Quality Assurance Report (QAR), inside their own site licence application or amendment. Foreign warehouses have also been removed from site licences, although the underlying obligation to keep those warehouses GMP-compliant remains fully in place.

For companies that shared a foreign supplier across several importers, the administrative load has grown. Weak supplier oversight, thin documentation, and immature CAPA systems now surface quickly. The organizations that move first, rebuild their evidence packages, and formalize their quality systems will protect market access. Those that wait risk refused applications, delayed shipments, and compliance action.

What Is GUI-0158 and Why It Matters Now

Direct answer: GUI-0158 is Health Canada's Good Manufacturing Practices Guide for Natural Health Products. Version 4.0 explains how Health Canada interprets the GMP requirements in Part 3 of the Natural Health Products Regulations. It replaced version 3 and came into force on March 4, 2026, after a six-month transition that began when it was published on September 4, 2025. It matters because it is the standard your site, and every foreign site you rely on, will be measured against.

GUI-0158 is guidance, not a new regulation. The legal requirements still live in Part 3 of the Natural Health Products Regulations. What version 4.0 does is modernize Health Canada's expectations around areas such as product specifications, testing, stability, recall readiness, and quality oversight, and it aligns NHP practice more closely with mainstream pharmaceutical quality thinking.

For a deeper walkthrough of the version 4.0 changes and what licence holders must do, see our companion guide, NHP GMP Guide Version 4.0 (GUI-0158): What Natural Health Product Licence Holders Must Do Now. This article focuses on the piece that has caught the most companies off guard, the disappearance of the FSRN.

How GUI-0158 affects compliance

Because Health Canada assesses GMP evidence against the current guide, every quality document you submit should reflect GUI-0158 version 4.0 expectations. Standard operating procedures, specifications, and stability protocols written against the older guidance may now read as incomplete. Aligning your documentation to the current guide is the baseline for a clean site licence review.

The End of the FSRN Process: What Actually Changed

Direct answer: On February 16, 2026, Health Canada eliminated the FSRN process and the requirement to list foreign warehouses on site licences. Foreign sites can no longer submit an FSRN authorization form, new FSRN applications are refused, and existing FSRNs are now marked discontinued on Health Canada's published list. GMP evidence for each foreign site must instead be filed within each importer's site licence application.

The change was communicated through Health Canada's Natural Health Products Site Licensing and Good Manufacturing Practices Inspection Bulletin, and it took effect without a prior notice period. That immediacy is the reason so many importers were caught mid-cycle. Here is what changed in practical terms.

Item	Before February 16, 2026	After February 16, 2026
FSRN authorization form	Foreign site could file one FSRN to support multiple importers	No longer accepted
New FSRN applications	Accepted and processed	Refused
Existing FSRNs	Active and usable as pre-cleared evidence	Marked discontinued on the published list
Foreign warehouses	Listed on the importer's site licence	Removed from site licences at amendment or renewal
Foreign site GMP evidence	Could ride on a shared, pre-cleared FSRN	Must be filed in each importer's own application
Foreign warehouse GMP duty	Required under Part 3	Still required under Part 3, no change

It is important to be clear about what did not change. GMP evidence was always required for every foreign site referenced on a site licence under the Natural Health Products Regulations. The FSRN was an administrative convenience, not a legal shortcut. Removing it does not create a new GMP obligation. It removes the mechanism that let one pre-cleared evidence package serve many importers. The obligation to keep foreign warehouses compliant with Part 3 also remains untouched, even though those warehouses no longer appear on the licence.

Why the FSRN mattered to industry

The FSRN gave real efficiencies. It allowed direct communication between a foreign site and Health Canada, reduced duplicate paperwork when a site supplied several Canadian importers, and let an approved FSRN act as pre-cleared evidence that qualified for shorter service standards. Its removal means importers should plan for closer coordination with foreign manufacturers and packagers, and for the possibility of repeated evidence submissions when several importers share one foreign site.

Who Is Now in Scope: Importers and Distributors

Direct answer: Importers are squarely in scope. Any company that imports NHPs into Canada must hold a site licence and must now submit foreign site GMP evidence directly within that licence application. Distributors are also bound by GMP. Under the Natural Health Products Regulations, distributors must comply with Part 3 GMP requirements even where a separate site licence activity is not triggered. Brand owners who import through a third party remain responsible for the compliance of their supply chain.

Many importers historically leaned on the foreign site or a shared FSRN to carry the GMP burden. That posture no longer works. The importer of record is now the party that must assemble and defend the evidence for each foreign manufacturer, packager, labeller, and testing site in its chain. The common exposure points are predictable:

Importers who never held their own complete GMP evidence packages because a supplier's FSRN covered them.
Distributors who assumed GMP was somebody else's responsibility and never built quality documentation of their own.
Brand owners who outsource importing and have limited visibility into the foreign site files that now underpin their market access.
Foreign sites that supplied multiple Canadian importers through one FSRN and must now support several separate submissions.

If your company sits in any of these groups, treat this as an active file, not a future project. Our regulatory affairs, licensing and import/export team is already rebuilding importer files created around the old FSRN model.

What Counts as Acceptable GMP Evidence Now

Direct answer: Health Canada accepts two broad forms of foreign site GMP evidence. The first is pre-cleared evidence, typically a GMP certificate from a recognized authority, or in some cases certain third-party certifications that partially meet the requirement when supported by the right documents. The second is a Quality Assurance Report (QAR) prepared by a qualified quality assurance person. Where pre-cleared evidence is not available, the QAR is the primary route.

Pre-cleared GMP evidence

Pre-cleared evidence is the smoother path because Health Canada can rely on an assessment already performed by a trusted body. It includes:

A GMP certificate issued by a qualified regulatory authority.
Certain third-party certifications, for example NSF/ANSI 173 Section 8 or a UL Dietary Supplement GMP certificate, which may partially satisfy the pre-cleared requirement when accompanied by the required supporting documents.

Pre-cleared evidence historically qualified for shorter service standards, which is one reason the loss of the FSRN shortcut stings.

The Quality Assurance Report (QAR)

Where pre-cleared evidence is not available, a QAR is submitted. The QAR is a report prepared by the quality assurance person responsible for the site, someone with the training, experience, and technical knowledge relating to the activities conducted and to Part 3 GMP. It is treated as an attestation by the applicant that the site meets all Part 3 requirements, and it is valid for one year from the date the quality assurance person completes it.

Health Canada expects a QAR to be supported by real records, not summaries. A credible QAR package includes:

Relevant standard operating procedures, for example product release, recalls, testing, and stability.
Records that support finished product release.
Testing documentation such as certificates of analysis.
Stability data and related records.

The one-year validity window is a planning trap. A QAR completed too early can expire before a slow multi-site application clears, so timing the QAR to the submission is part of the strategy.

A Step-by-Step Transition Plan

Companies that treat this as a structured project, rather than a scramble, close the gap faster. The following sequence works well in practice.

Map your foreign sites. List every foreign manufacturer, packager, labeller, and testing site tied to your imports, and note which ones relied on an FSRN.
Confirm licence status. Check Health Canada's published list to see which of your foreign sites are now marked discontinued, and identify every site licence and amendment affected.
Choose the evidence route per site. Decide, site by site, whether pre-cleared evidence exists or whether a QAR is required.
Request evidence early. Contact foreign partners now, since assembling GMP certificates, SOPs, certificates of analysis, and stability data takes time across borders.
Align documents to GUI-0158 v4.0. Review incoming SOPs and specifications against the current guide, and remediate gaps before they reach Health Canada.
Sequence QAR timing. Schedule QAR completion close to your submission date to protect the one-year validity window.
File the amendment or application. Submit complete foreign site GMP evidence within each importer's site licence application or amendment.
Keep warehouses compliant. Even though foreign warehouses no longer appear on the licence, maintain Part 3 GMP compliance and documentation for every storage facility.

Compliance Checklist

Use this checklist to test whether your organization is ready for the post-FSRN regime.

Every foreign site in your supply chain is identified and mapped to a specific importer file.
You have confirmed which of your FSRNs are now marked discontinued.
Each foreign site has a chosen evidence route: pre-cleared certificate or QAR.
Pre-cleared certificates (GMP certificate, NSF/ANSI 173 Section 8, or UL Dietary Supplement GMP) are current and supported by required documents.
QARs are prepared by a qualified quality assurance person and supported by SOPs, release records, certificates of analysis, and stability data.
QAR completion dates are sequenced to your submission timeline to protect the one-year validity.
SOPs and specifications reflect GUI-0158 version 4.0 expectations.
Supplier qualification and oversight procedures are documented and current.
Foreign warehouses remain GMP-compliant under Part 3, with records retained.
A CAPA process is in place to correct any gaps identified during the transition.

Common Mistakes to Avoid

Even experienced teams stumble during this transition. The most frequent and most costly errors include:

Assuming the FSRN still counts. A discontinued FSRN is not acceptable GMP evidence. Continuing to reference it will not satisfy a review.
Treating the change as optional. The policy took effect immediately on February 16, 2026, with no grace period built in.
Letting a QAR expire. Completing the QAR months before a slow application clears can push it past its one-year validity.
Submitting thin QARs. A report without SOPs, release records, certificates of analysis, and stability data will not carry the file.
Forgetting foreign warehouses. Removal from the licence does not remove the Part 3 GMP obligation for storage sites.
Poor supplier coordination. Waiting until the last moment to request cross-border documentation stalls submissions, especially where several importers share one site.
Using outdated forms. Health Canada has flagged that current site licence forms and guidance are outdated and will be removed, so confirm you are working from current materials before you file.

How MFLRC Can Help

MFLRC is a Canadian regulatory and quality consultancy that helps NHP manufacturers, importers, distributors, and brand owners keep market access through exactly this kind of transition. Our work is practical and defensible, built to survive a Health Canada review rather than just fill a form. We support clients across the full site licensing lifecycle:

Gap assessments that benchmark your current documentation and foreign site evidence against GUI-0158 version 4.0 and Part 3 of the Natural Health Products Regulations.
Site licence and amendment support through our regulatory affairs, licensing and import/export practice, including rebuilding importer files that relied on FSRNs.
Quality Assurance Report preparation and review, coordinated with a qualified quality assurance person, with the SOPs, release records, testing documentation, and stability data Health Canada expects.
SOP development and QMS build-out aligned to the current GMP guide.
Supplier qualification and foreign site oversight so your evidence packages hold up across borders.
Audit readiness, mock inspections, and CAPA to close findings before they reach a regulator.

If your FSRN was central to how you import into Canada, this is the moment to act. Book a consultation with MFLRC and let our team map your exposure, rebuild your evidence packages, and protect your Canadian market access.

Book a Consultation with MFLRC

Frequently Asked Questions

Are FSRNs still accepted by Health Canada?

No. As of February 16, 2026, Health Canada no longer accepts FSRN authorization forms or new FSRN applications. Existing FSRNs are marked discontinued on Health Canada's published list and cannot be used as GMP evidence. Foreign site GMP evidence must now be filed inside each importer's site licence application.

When did GUI-0158 come into force?

GUI-0158 version 4.0 came into force on March 4, 2026. It was published on September 4, 2025, with a six-month transition period, and it replaces version 3 as Health Canada's interpretation of the GMP requirements in Part 3 of the Natural Health Products Regulations.

What GMP evidence do importers need to submit now?

Importers must submit either pre-cleared evidence, such as a GMP certificate from a recognized authority or certain supported third-party certifications, or a Quality Assurance Report (QAR) prepared by a qualified quality assurance person, for each foreign site referenced on the licence.

What is a Quality Assurance Report (QAR)?

A QAR is a report prepared by the quality assurance person responsible for a site, attesting that the site meets all Part 3 GMP requirements. It must be supported by SOPs, finished product release records, testing documentation such as certificates of analysis, and stability data. It is valid for one year from the date it is completed.

Do distributors of NHPs need to follow GMP?

Yes. Under the Natural Health Products Regulations, distributors must comply with Part 3 GMP requirements. Distributors that assumed GMP was solely the manufacturer's responsibility should build their own quality documentation and supplier oversight.

My foreign warehouse was removed from my site licence. Do I still need GMP there?

Yes. Health Canada removed the requirement to list foreign warehouses on site licences, but the obligation for those warehouses to comply with Part 3 GMP has not changed. Importers remain responsible for ensuring every foreign storage facility handling NHPs meets applicable GMP requirements.

Conclusion

The 2026 NHP GMP reset is not a paperwork tweak. GUI-0158 version 4.0 raised the quality bar, and the removal of the FSRN process removed the shortcut many importers leaned on to meet it. The obligation to prove foreign site GMP was always there. What has changed is that the proof must now travel with each importer's own site licence application, backed by documentation that stands up to scrutiny.

The companies that treat this as an active compliance project, mapping their sites, choosing the right evidence route, aligning documents to the current guide, and timing their QARs, will protect their access to the Canadian market. The ones that wait risk refused applications and stalled shipments. If your supply chain relied on an FSRN, the safest next step is a structured gap assessment and a rebuilt evidence package, and MFLRC is ready to help you get there.